Overexpression of SphK1 Enhances Cell Proliferation and Invasion in Triple-negative Breast Cancer Via the PI3K/AKT Signaling Pathway

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2016 Feb 10

PMID 26857281

Citations 19

Authors

Jun Li

Zhangjun Song

YiYu Wang

Yue Yin

Ying Liu

Rong Yuan

Xing Nan

Affiliations

Soon will be listed here.

Abstract

Sphingosine kinase 1 (SphK1) expression is elevated in various cancers and is associated with shorter survival times for patients. However, the molecular mechanism of SphK1 up-regulation in triple-negative breast cancer (TNBC) remains unclear. In this study, we assayed the expression level of SphK1 in TNBC tissues by qRT-PCR and immunohistochemistry. The level of S1P was quantified by ELISA in the serum of TNBC patients. Our results found that the levels of SphK1 and S1P were significantly increased in TNBC patients compared with normal control. Furthermore, knockdown of SphK1 with siRNA decreased TNBC cell proliferation and inhibited cell migration/invasion. These data suggest that SphK1 has an important role in TNBC and presents an attractive therapeutic target for the treatment for TNBC.

Citing Articles

Influence of SphK1 on Inflammatory Responses in Lipopolysaccharide-Challenged RAW 264.7 Cells.

Wei C, Song L, Peng Z, Wang X Cell Biochem Biophys. 2024; 82(3):2511-2521.

PMID: 38909173 DOI: 10.1007/s12013-024-01364-z.

Integrative roles of sphingosine kinase in liver pathophysiology.

Kim K, Shin E, Yang J, Ki S Toxicol Res. 2023; 39(4):549-564.

PMID: 37779595 PMC: 10541397. DOI: 10.1007/s43188-023-00193-1.

Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure.

Polyak S, Crispe I, Baumert T Pathogens. 2021; 10(1).

PMID: 33430338 PMC: 7825776. DOI: 10.3390/pathogens10010044.

The Tumorigenic Effect of Sphingosine Kinase 1 and Its Potential Therapeutic Target.

Wang X, Sun Y, Peng X, Naqvi S, Yang Y, Zhang J Cancer Control. 2020; 27(1):1073274820976664.

PMID: 33317322 PMC: 8480355. DOI: 10.1177/1073274820976664.

Identifying novel sphingosine kinase 1 inhibitors as therapeutics against breast cancer.

Khan F, Lai D, Anwer R, Azim I, Ahmad Khan M J Enzyme Inhib Med Chem. 2019; 35(1):172-186.

PMID: 31752564 PMC: 6882459. DOI: 10.1080/14756366.2019.1692828.

References

Liu Y, Baglia M, Zheng Y, Blot W, Bao P, Cai H . ALDH1A1 mRNA expression in association with prognosis of triple-negative breast cancer. Oncotarget. 2015; 6(38):41360-9. PMC: 4747411. DOI: 10.18632/oncotarget.6023. View

Malavaud B, Pchejetski D, Mazerolles C, de Paiva G, Calvet C, Doumerc N . Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur J Cancer. 2010; 46(18):3417-24. DOI: 10.1016/j.ejca.2010.07.053. View

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Tsukamoto S, Huang Y, Kumazoe M, Lesnick C, Yamada S, Ueda N . Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKs. Mol Cancer Ther. 2015; 14(10):2303-12. DOI: 10.1158/1535-7163.MCT-15-0185. View

Hait N, Oskeritzian C, Paugh S, Milstien S, Spiegel S . Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta. 2006; 1758(12):2016-26. DOI: 10.1016/j.bbamem.2006.08.007. View

Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, Minozzi M . Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther. 2015; 8:177-93. PMC: 4303459. DOI: 10.2147/OTT.S67673. View

Bansal N, Petrie K, Christova R, Chung C, Leibovitch B, Howell L . Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer. Oncotarget. 2015; 6(33):34087-105. PMC: 4741438. DOI: 10.18632/oncotarget.6048. View

Datta A, Loo S, Huang B, Wong L, Tan S, Tan T . SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. Oncotarget. 2014; 5(15):5920-33. PMC: 4171602. DOI: 10.18632/oncotarget.1874. View

Fulford L, Reis-Filho J, Ryder K, Jones C, Gillett C, Hanby A . Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007; 9(1):R4. PMC: 1851397. DOI: 10.1186/bcr1636. View

10.

Chen M, Yen C, Cheng C, Wu R, Huang S, Yu C . Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. Oncotarget. 2015; 6(27):23594-608. PMC: 4695139. DOI: 10.18632/oncotarget.4335. View

11.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

12.

Kim H, Yoon G, Ryu J, Cho Y, Choi J, Lee Y . Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer. Oncotarget. 2015; 6(29):26746-56. PMC: 4694949. DOI: 10.18632/oncotarget.4818. View

13.

Pyne N, Tonelli F, Lim K, Long J, Edwards J, Pyne S . Sphingosine 1-phosphate signalling in cancer. Biochem Soc Trans. 2012; 40(1):94-100. DOI: 10.1042/BST20110602. View

14.

Tan S, Khin L, Wong L, Yan B, Ong C, Datta A . Sphingosine kinase 1 promotes malignant progression in colon cancer and independently predicts survival of patients with colon cancer by competing risk approach in South asian population. Clin Transl Gastroenterol. 2014; 5:e51. PMC: 3940836. DOI: 10.1038/ctg.2013.21. View

15.

Brenton J, Carey L, Ahmed A, Caldas C . Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol. 2005; 23(29):7350-60. DOI: 10.1200/JCO.2005.03.3845. View

16.

Yang L, Weng W, Sun Z, Fu X, Ma J, Zhuang W . SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo. Biochem Biophys Res Commun. 2015; 460(4):903-8. DOI: 10.1016/j.bbrc.2015.03.114. View

17.

Liu S, Huang J, Qin M, Su Y, Lai M, Jiang H . Sphingosine kinase 1 enhances colon cancer cell proliferation and invasion by upregulating the production of MMP-2/9 and uPA via MAPK pathways. Int J Colorectal Dis. 2012; 27(12):1569-78. DOI: 10.1007/s00384-012-1510-y. View

18.

Xu Y, Dong B, Huang J, Kong W, Xue W, Zhu Y . Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression. Oncotarget. 2015; 7(3):3233-44. PMC: 4823102. DOI: 10.18632/oncotarget.6564. View

19.

Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C . Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009; 9(1):29-33. DOI: 10.3816/CBC.2009.n.005. View

20.

Zhu L, Wang Z, Lin Y, Chen Z, Liu H, Chen Y . Sphingosine kinase 1 enhances the invasion and migration of non-small cell lung cancer cells via the AKT pathway. Oncol Rep. 2014; 33(3):1257-63. DOI: 10.3892/or.2014.3683. View